Discovery of Tropifexor (LJN452), a Highly Potent Non-bile Acid FXR Agonist for the Treatment of Cholestatic Liver Diseases and Nonalcoholic Steatohepatitis (NASH) | Journal of Medicinal Chemistry
![UK - Okt 2019 - Aspirin - Acetylsalicylsyra - England Redaktionell Foto - Bild av läkarbehandling, reumatiker: 160586505 UK - Okt 2019 - Aspirin - Acetylsalicylsyra - England Redaktionell Foto - Bild av läkarbehandling, reumatiker: 160586505](https://thumbs.dreamstime.com/b/uk-okt-aspirin-acetylsalicylsyra-england-som-ocks%C3%A5-kallas-%C3%A4r-ett-sm%C3%A4rtlindrande-medel-anv%C3%A4nds-dagligen-f%C3%B6r-att-behandla-160586505.jpg)
UK - Okt 2019 - Aspirin - Acetylsalicylsyra - England Redaktionell Foto - Bild av läkarbehandling, reumatiker: 160586505
![Discovery of Tropifexor (LJN452), a Highly Potent Non-bile Acid FXR Agonist for the Treatment of Cholestatic Liver Diseases and Nonalcoholic Steatohepatitis (NASH) | Journal of Medicinal Chemistry Discovery of Tropifexor (LJN452), a Highly Potent Non-bile Acid FXR Agonist for the Treatment of Cholestatic Liver Diseases and Nonalcoholic Steatohepatitis (NASH) | Journal of Medicinal Chemistry](https://pubs.acs.org/cms/10.1021/acs.jmedchem.7b00907/asset/images/medium/jm-2017-00907n_0002.gif)
Discovery of Tropifexor (LJN452), a Highly Potent Non-bile Acid FXR Agonist for the Treatment of Cholestatic Liver Diseases and Nonalcoholic Steatohepatitis (NASH) | Journal of Medicinal Chemistry
![Frontiers | Aspirin Effect on Staphylococcus aureus—Platelet Interactions During Infectious Endocarditis Frontiers | Aspirin Effect on Staphylococcus aureus—Platelet Interactions During Infectious Endocarditis](https://www.frontiersin.org/files/Articles/486977/fmed-06-00217-HTML/image_m/fmed-06-00217-g001.jpg)
Frontiers | Aspirin Effect on Staphylococcus aureus—Platelet Interactions During Infectious Endocarditis
Bipacksedel: Information till användaren Acetylsalicylsyra Teva 75 mg, 150 mg och 160 mg tabletter acetylsalicylsyra Läs noga
![Cysteinyl-leukotriene pathway as a new therapeutic target for the treatment of atherosclerosis related to obstructive sleep apnea syndrome - ScienceDirect Cysteinyl-leukotriene pathway as a new therapeutic target for the treatment of atherosclerosis related to obstructive sleep apnea syndrome - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S1043661818301749-ga1.jpg)